De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Guangdong Hybribio BiotechLtd Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jianyu Wang

Algemeen directeur

CN¥2.0m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.2yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	7.1yrs
Gemiddelde ambtstermijn bestuur	7.7yrs

Recente managementupdates

Recent updates

Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?

Sep 29

Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) 77% Share Price Surge Not Quite Adding Up

Aug 19

Guangdong Hybribio BiotechLtd (SZSE:300639) Is Reducing Its Dividend To CN¥0.065

May 22

There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings

May 03

CEO

Jianyu Wang (63 yo)

2.2yrs

Tenure

CN¥2,028,700

Compensatie

Ms. Jianyu Wang is the General Manager at Guangdong Hybribio Biotech Co.,Ltd. since August 31, 2022 and was its Executive Deputy General Manager until August 31, 2022. She has been Director at Guangdong Hy...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jianyu Wang	GM & Director	2.2yrs	CN¥2.03m	geen gegevens
Qinghui Li	Finance Director & Accounting Supervisor	10.5yrs	CN¥671.50k	0.0071% CN¥ 309.2k
Longxu Xie	Deputy GM & Director	14.1yrs	CN¥1.15m	0.059% CN¥ 2.5m
Zhisheng Guan	Executive Deputy GM & Non Independent Director	no data	CN¥2.97m	0.57% CN¥ 24.7m
Yi Chen	Deputy GM & Board Secretary	no data	CN¥715.90k	0.013% CN¥ 549.7k
Danrong Weng	Deputy General Manager	3.8yrs	CN¥720.50k	0.0055% CN¥ 240.0k

7.1yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300639 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jianyu Wang	GM & Director	8.1yrs	CN¥2.03m	geen gegevens
Longxu Xie	Deputy GM & Director	4yrs	CN¥1.15m	0.059% CN¥ 2.5m
Zhisheng Guan	Executive Deputy GM & Non Independent Director	14.1yrs	CN¥2.97m	0.57% CN¥ 24.7m
Meilan Qiu	Supervisor	7.3yrs	geen gegevens	geen gegevens
Weixiong Huang	Vice Chairman of the Board	14.1yrs	CN¥300.00k	geen gegevens
Xiaoyan Yang	Director	14.1yrs	CN¥120.00k	geen gegevens
Qiaozhong Guan	Chairman of the Board	14.1yrs	CN¥2.17m	geen gegevens
Wanjian Xu	Employee Representative Supervisor	11.2yrs	geen gegevens	geen gegevens
Ruijun Ma	Chairman of the Supervisory Board	5.1yrs	geen gegevens	geen gegevens
Youlin Qiao	Independent Director	2.2yrs	CN¥120.00k	geen gegevens
Chunxue Yang	Independent Director	2.2yrs	CN¥120.00k	geen gegevens
Yingshi Chen	Independent Director	2.2yrs	CN¥120.00k	geen gegevens

7.7yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300639 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

Guangdong Hybribio BiotechLtd Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, May 14, 2024

Less than half of directors are independent

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Announces Director Appointments

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Recent updates

Guangdong Hybribio Biotech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?

Second quarter 2024 earnings released: CN¥0.11 loss per share (vs CN¥0.088 profit in 2Q 2023)

Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) 77% Share Price Surge Not Quite Adding Up

Investor sentiment improves as stock rises 44%

New minor risk - Share price stability

Guangdong Hybribio Biotech Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) announces an Equity Buyback for CNY 60 million worth of its shares.

Guangdong Hybribio BiotechLtd (SZSE:300639) Is Reducing Its Dividend To CN¥0.065

Dividend of CN¥0.065 announced

There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, May 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 24% overvalued

Guangdong Hybribio Biotech Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) announces an Equity Buyback for CNY 60 million worth of its shares.

Investor sentiment deteriorates as stock falls 16%

Guangdong Hybribio Biotech Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released: EPS: CN¥0.076 (vs CN¥0.78 in 3Q 2022)

Guangdong Hybribio Biotech Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.088 (vs CN¥0.73 in 2Q 2022)

Hybribio Showcases Cutting-Edge Cervical Cancer HPV Diagnostic Solutions At ADLM 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Guangdong Hybribio Biotech Co.,Ltd. Announces Cash Dividend on A Shares for Year 2022, Payable on May 22, 2023

Investor sentiment deteriorates as stock falls 19%

Full year 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on October 10, 2022.

Third quarter 2022 earnings released: EPS: CN¥1.17 (vs CN¥0.59 in 3Q 2021)

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Announces Director Appointments

Second quarter 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.50 in 2Q 2021)

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Declares Dividend Implementation of A Shares for the Year 2021, Payable on April 29, 2022

Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Guangdong Hybribio Biotech Co.,Ltd. Announces Final Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Now 22% undervalued

Investor sentiment improved over the past week

Now 22% undervalued

Now 21% undervalued

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.88 (vs CN¥0.54 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.75 (vs CN¥0.43 in 2Q 2020)

Investor sentiment improved over the past week

Guangdong Hybribio Biotech Co.,Ltd. Declares Dividend Implementation of A Shares for the Year 2020, Payable on May 28, 2021

Guangdong Hybribio Biotech Co.,Ltd. Approves Profit Distribution for 2020

First quarter 2021 earnings released: EPS CN¥0.73 (vs CN¥0.09 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥0.70 in FY 2019)

New 90-day low: CN¥32.33

Guangdong Hybribio Biotech Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 15, 2021

New 90-day low: CN¥33.91

Investor sentiment deteriorated over the past week

New 90-day low: CN¥42.94

Third quarter earnings released

Third quarter earnings released

Guangdong Hybribio Biotech Co.,Ltd. to Report Q3, 2020 Results on Oct 23, 2020

First half earnings released

Guangdong Hybribio Biotech Co.,Ltd. to Report First Half, 2020 Results on Aug 15, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden